Thomas Cosgriff, MD
Hematology & Oncology · Metairie, LANPI 1750346938
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,027 of the $2,407 with a category attached, or 84.2%. It is spread thinly across 36 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. 2024 is the largest year on record at $929, more than ten times the $65 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in LA, where the typical reported total is $4,451.
Across 121 payments — averaging $19.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$274
- Johnson & Johnson$223
- Pfizer$213
- Bristol Myers Squibb$192
- Astellas Pharma US Inc$166
- Sanofi$150
- plus $1K from 30 others
Across 48 payments — averaging $4453.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$144K
- AstraZeneca$21K
- Amgen$15K
- Pharmacyclics LLC, An Abbvie Company$15K
- Takeda Pharmaceuticals U.S.A., Inc.$10K
- E.r. Squibb & Sons, L.L.C.$3K
- plus $6K from 3 others
What the payments were for
- Food & beverage$2,02784%
- Education$37916%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead(2 entities) | 17 | $274 |
| Johnson & Johnson(2 entities) | 5 | $223 |
| Pfizer | 13 | $213 |
| Bristol Myers Squibb | 11 | $192 |
| Astellas Pharma US Inc | 7 | $166 |
| Sanofi | 9 | $150 |
| Daiichi Sankyo Inc. | 5 | $125 |
| AstraZeneca | 6 | $104 |
| Sanofi-aventis U.S. LLC | 1 | $95 |
| Novartis | 6 | $93 |
| Genentech USA, Inc. | 4 | $91 |
| AbbVie | 3 | $71 |
| Regeneron Healthcare Solutions, Inc. | 3 | $62 |
| Intuitive Surgical | 1 | $56 |
| Merck | 3 | $49 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $38 |
| Amgen | 3 | $37 |
| GSK | 2 | $35 |
| Lilly USA, LLC | 2 | $33 |
| Mylan Institutional Inc. | 2 | $29 |
| Seagen Inc. | 1 | $26 |
| Servier Pharmaceuticals LLC | 1 | $24 |
| Sobi, Inc | 1 | $21 |
| Beigene USA, Inc. | 1 | $19 |
| Tempus AI, Inc | 1 | $17 |
| ADC Therapeutics America, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Array Biopharma Inc | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Kyowa Kirin, Inc. | 1 | $15 |
| CTI Biopharma Corp. | 1 | $15 |
| EMD Serono, Inc. | 1 | $15 |
| Mirati Therapeutics, Inc. | 1 | $14 |
| Karyopharm Therapeutics Inc. | 1 | $14 |
| Stemline Therapeutics Inc. | 1 | $14 |
How this compares
$2,407 in reported general payments places this provider in the 30th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 27 | $439,395 |
| JakafiRuxolitinib Phosphate | 18 | $340,809 |
| InrebicFedratinib Dihydrochloride | 13 | $338,908 |
| XospataGilteritinib Fumarate | 12 | $338,510 |
| CalquenceAcalabrutinib Maleate | 21 | $338,283 |
| RevlimidLenalidomide | 17 | $326,236 |
| TruqapCapivasertib | 11 | $208,567 |
| IbrancePalbociclib | 12 | $191,997 |
| XtandiEnzalutamide | 12 | $173,384 |
| XareltoRivaroxaban | 44 | $42,170 |
| EliquisApixaban | 42 | $33,458 |
| Abiraterone Acetate | 15 | $23,625 |
| Imatinib Mesylate | 15 | $7,322 |
| Anastrozole | 145 | $2,796 |
| Oxycodone Hcl | 99 | $2,589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbInrebic, Revlimid | $192 | $665,14330 claims |
| AstraZenecaCalquence, Truqap | $104 | $546,85132 claims |
| Astellas Pharma US IncXospata, Xtandi | $166 | $511,89324 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $38 | $439,39527 claims |
| PfizerIbrance, Eliquis | $213 | $225,45554 claims |
| Johnson & JohnsonXarelto | $223 | $42,17044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Metairie
- Ashish UdhrainMetairie$76K
- Hana SafahBaton Rouge$2M
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Nakhle SabaBaton Rouge$842K
- Marc MatranaNew Orleans$757K
- Prakash PeddiShreveport$405K
- Sanjay JunejaBaton Rouge$346K
- Lingling duNew Orleans$173K
- Kamran ShahidLake Charles$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.